Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome (Q46909610)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 November 2007

Language	Label	Description	Also known as
English	Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome	scientific article published on 8 November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

14

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

Elizabeth J Shpall

11

object named as

E J Shpall

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

Richard E Champlin

2

object named as

R E Champlin

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

20

object named as

S Giralt

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

12

object named as

I Khouri

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

author name string

M de Lima

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

P F Thall

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

X Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

T G Martin

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

J D Cook

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

G McCormick

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

M Qazilbash

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

P Kebriaei

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

D Couriel

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

P Anderlini

13

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

K W Chan

15

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

B S Andersson

16

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

P A Patah

17

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

Z Caldera

18

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

E Jabbour

19

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

publication date

8 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

22

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

258-264

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Dose-finding based on efficacy-toxicity trade-offs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

21 January 2018

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression Models and Life-Tables (with discussion)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

7 January 2021

based on heuristic

inferred from DOI database lookup

Modern Applied Statistics with S

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405014

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2405014

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17989720

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46909610&oldid=2208239216"